• <rp id="mz6wu"><meter id="mz6wu"></meter></rp><rp id="mz6wu"></rp>
  • <ruby id="mz6wu"><optgroup id="mz6wu"></optgroup></ruby><rt id="mz6wu"><meter id="mz6wu"></meter></rt>

    <cite id="mz6wu"><form id="mz6wu"></form></cite><video id="mz6wu"><menuitem id="mz6wu"><option id="mz6wu"></option></menuitem></video>
    <source id="mz6wu"><nav id="mz6wu"></nav></source>
  • <tt id="mz6wu"></tt>
    <tt id="mz6wu"><noscript id="mz6wu"><samp id="mz6wu"></samp></noscript></tt><tt id="mz6wu"><noscript id="mz6wu"><label id="mz6wu"></label></noscript></tt>
  • Filter By:
    • News
      April 12, 2018

      Doravirine Effective in Treatment-naive Adults With HIV

      A study comparing the efficacy of doravirine and ritonavir-boosted darunavir in adult patients with HIV who were treatment-naive found that doravirine was …

      Read Article
    • News
      April 10, 2018

      Record Number Of Specialty Pharmacies Now Have Accreditation

      The number of accredited specialty pharmacies nearly doubled between 2015 and 2017, according to research by the Drug Channels Institute. The fastest-growi…

      Read Article
    • News
      April 09, 2018

      Pharmacists Can Improve Outcomes

      Pharmacists can improve optimization of medication therapies to improve outcomes and reduce costs. Strategies include allowing pharmacist access to complet…

      Read Article
    • News
      March 22, 2018

      Cimzia Label Update Provides New Information For Women Of Childbearing Age

      The FDA approved a label update of UCB's Cimzia, or certolizumab pegol, to include new data showing a negligible to low risk for drug transfer through plac…

      Read Article
    • News
      March 05, 2018

      Review Finds Switching From Reference Product To Biosimilar ‘Not Inherently Dangerous’

      A review in the journal Drugs found that moving to a biosimilar from a reference drug "is not inherently dangerous, and that patients, healthcare professio…

      Read Article
    • News
      February 13, 2018

      Novartis Gains U.S. Approval For Glatopa For Multiple Sclerosis

      Novartis's Sandoz division has won U.S. approval for a larger dose of its Glatops drug for multiple sclerosis (MS). Click Here to view the original arti…

      Read Article

    A smaller focus to make a much larger impact. Our goal is to deliver on every promise we make

    Our Mission

    Learn More